On the morning of January 8, 2016, National Science and Technology Awards Conference 2015 was grandly held at the Great Hall of the People full of lights and scents of spring. National leaders attended the conference and presented awards to the winners. The research project of Professor Li Xiaokun, President of Wenzhou University, titled “Innovative Theory and Key Measures for New Characteristics and Prevention of Chronic Skin Ulcers on Human Body in China” was awarded the First Prize of National Science and Technology Progress Award.

 This project is the product of interdisciplinary integration among traumatic medicine, pharmaceutical science, medical apparatus and materials science in China, reflecting the international leading treatment and research level of China in the fields of trauma repair, chronic disease and geriatric diseases. At present, more than 100 million persons need trauma repair in China every year; the average length of hospitalization for chronic wounds is 21 days, and the average treatment cost exceeds 12,000 yuan, which imposes a heavy burden on society and families. Professor Li Xiaokun and his team have been committed to the basic and applied research of biopharmaceuticals represented by Fibroblast Growth Factors (FGFs) for more than 20 years. They have taken the lead in solving a series of genetic engineering problems in the process of FGFs protein drug preparation, and first developed the national first-class new drug “recombinant human basic fibroblast growth factor for external use” (Gaifu) with independent intellectual property rights in the world, which is 4 years earlier than Japan and 7 years earlier than the United States. They have provided innovative drugs with active repair function for the treatment of severe trauma and chronic skin ulcers. These drugs have been widely used in many medical fields such as military medical treatment, emergency rescue, wound healing and plastic surgery.

 Professor Li’s research achievements have been successfully industrialized by Nanhai Longtime Pharmaceutical Co., Ltd., and have been included in the National High-tech Industrialization Demonstration Projects by the National Development and Reform Commission. At present, “recombinant human basic fibroblast growth factor for external use” (Gaifu) has been used by more than 2,000 hospitals across the country to cure more than 80 million patients, creating significant social and economic benefits. Fibroblast Growth Factors (FGFs) drugs are not only included in Chinese Pharmacopoeia, but also listed as clinician-guided medications by Wound Healing and Ulcers of the Skin Diagnosis and Therapy published by Springer and The Foot in Diabetes published by Wiley.

 Thanks to the outstanding achievements in the technical and theoretical research of FGFs drugs for the treatment of chronic ulcers and refractory wounds, Professor Li Xiaokun as the main contributor of the research project titled “Innovative Theory and Key Measures for New Characteristics and Prevention of Chronic Skin Ulcers on Human Body in China” won the First Prize of National Science and Technology Progress Award in 2005. Previously, Professor Li Xiaokun had successively won the Second Prize of National Award for Technological Invention and the First Prize of Science and Technology Award of the Ministry of Education.